The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and Panel of Infectious Diseases Experts, has extended the interim authorisation of Pfizer-BioNTech COVID-19 Vaccine to include use in adolescents aged 12 to 15 years on 18 May 2021.
Further data from ongoing studies show that it is highly efficacious in adolescents with a vaccine efficacy rate of 100% compared to 95% in adults.
There is currently insufficient data on the vaccine efficacy against re-infection and asymptomatic infection, and the ongoing Phase III study is expected to generate more data to address these.
2 doses 21 days apart
Adolescents seem to react more strongly to the vaccine but there were no serious adverse effects in the 2000 patients studied.
Common reactions included: injection site pain, fatigue, headache, chills and fever.
There was a low rate of allergic reactions but since the study population was small, post-marketing surveillance is still continuing to monitor the incidence of adverse reactions.
If you are concerned about the vaccine or have any further questions please reach out to our team.